These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9266630)

  • 21. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus infection: when silence is deception.
    Racanelli V; Rehermann B
    Trends Immunol; 2003 Aug; 24(8):456-64. PubMed ID: 12909460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates.
    Li D; Wang X; von Schaewen M; Tao W; Zhang Y; Heller B; Hrebikova G; Deng Q; Sun Q; Ploss A; Zhong J; Huang Z
    J Infect Dis; 2017 Jun; 215(12):1824-1831. PubMed ID: 28398489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunopathogenesis of hepatitis C virus infection.
    Nelson DR
    Clin Liver Dis; 2001 Nov; 5(4):931-53. PubMed ID: 11685802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).
    Berger A; Giroglou T; Leutz A; Ogbomo H; Pfaff K; Teuber G; Cinatl J; van Laer D; Doerr HW
    J Clin Virol; 2009 Sep; 46(1):55-60. PubMed ID: 19560398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine.
    Thimme R; Neumann-Haefelin C; Boettler T; Blum HE
    Biol Chem; 2008 May; 389(5):457-67. PubMed ID: 18953713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees.
    Nascimbeni M; Mizukoshi E; Bosmann M; Major ME; Mihalik K; Rice CM; Feinstone SM; Rehermann B
    J Virol; 2003 Apr; 77(8):4781-93. PubMed ID: 12663785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of neutralizing antibodies and cellular immunity in hepatitis C virus infection].
    Inchauspé G
    Transfus Clin Biol; 2001 Dec; 8(6):471-4. PubMed ID: 11802609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HCV infection and specific T lymphocyte immunity].
    Shi JJ; Zhang JY; Zhang XX; Wang FS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):170-4. PubMed ID: 27095758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the analysis of hepatitis C virus specific T cell responses.
    Zhang X; Dou J; Germann MW
    Mini Rev Med Chem; 2011 Feb; 11(2):106-13. PubMed ID: 21222581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
    Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
    J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cell response in hepatitis C virus infection.
    Neumann-Haefelin C; Blum HE; Chisari FV; Thimme R
    J Clin Virol; 2005 Feb; 32(2):75-85. PubMed ID: 15653409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of T cell immunity in hepatitis C virus infections.
    Claassen MA; Janssen HL; Boonstra A
    Curr Opin Virol; 2013 Aug; 3(4):461-7. PubMed ID: 23735335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
    Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
    Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibodies in hepatitis C virus infection.
    Zeisel MB; Fafi-Kremer S; Fofana I; Barth H; Stoll-Keller F; Doffoel M; Baumert TF
    World J Gastroenterol; 2007 Sep; 13(36):4824-30. PubMed ID: 17828813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver tolerance and the manipulation of immune outcomes.
    Holz LE; McCaughan GW; Benseler V; Bertolino P; Bowen DG
    Inflamm Allergy Drug Targets; 2008 Mar; 7(1):6-18. PubMed ID: 18473895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model.
    Soguero C; Joo M; Chianese-Bullock KA; Nguyen DT; Tung K; Hahn YS
    J Virol; 2002 Sep; 76(18):9345-54. PubMed ID: 12186917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunology of hepatitis C: clinical significance of T cell response].
    Shin EC
    Korean J Hepatol; 2006 Jun; 12(2):140-53. PubMed ID: 16804339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral escape and the failure of cellular immune responses.
    Klenerman P; Lechner F; Kantzanou M; Ciurea A; Hengartner H; Zinkernagel R
    Science; 2000 Sep; 289(5487):2003. PubMed ID: 11032545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.